Estudo da atividade dos sulfatos de condroitina e glucosamina na formação de vasos sanguíneos em modelos in vitro e in vivo
| Ano de defesa: | 2012 |
|---|---|
| Autor(a) principal: | |
| Orientador(a): | |
| Banca de defesa: | , , , |
| Tipo de documento: | Tese |
| Tipo de acesso: | Acesso aberto |
| dARK ID: | ark:/57462/0013000005d5g |
| Idioma: | por |
| Instituição de defesa: |
Universidade Federal Rural de Pernambuco
|
| Programa de Pós-Graduação: |
Programa de Pós-Graduação em Biociência Animal
|
| Departamento: |
Departamento de Morfologia e Fisiologia Animal
|
| País: |
Brasil
|
| Palavras-chave em Português: | |
| Palavras-chave em Inglês: | |
| Área do conhecimento CNPq: | |
| Link de acesso: | http://www.tede2.ufrpe.br:8080/tede2/handle/tede2/4574 |
Resumo: | Chondroitin Sulfate (CS) and Glucosamine Sulfate (GS) are functional constituents of vertebrate tissues. GS is an amino sugar and CS is part of the glucosaminoglycans group (GAGs). Studies have suggested CS and GS to have anti-inflammatory properties, however it has also been shown that these compounds promote scarring and proliferation of fibroblasts, which express molecules important for blood vessel growth (angiogenesis). This study was aimed at evaluating the effects of CS and GS on in vitro models regarding cell viability (cytotoxicity - MTT), proliferation (BrdU incorporation) and differentiation (tubulogenesis in Matrigel support) on human umbilical vein endothelial cells (HUVEC line). In vivo angiogenesis was also evaluated in (1) extraembryonic membranes of Gallus domesticus (number of chorioallantoic vessels - CAM assay and vitelinic YSM assay; and fractal geometry analysis); (2) and subcutaneous tissue of adult mice (Mus muscullus) by hemoglobin quantification (Spectroscopy) in Gelfoam implants. In the HUVEC assay, both CS and GS (1-3000 g/mL) displayed partial cytotoxic effect (~50% viability), but only in the highest tested concentrations (3000 and 1000 g/mL). It was observed that CS (3 g/mL), but not GS, promoted proliferation and tubulogenesis of HUVEC in 40% (P < 0.05) and 64% (P < 0.05), respectively, relative to control (RPMI-1640 medium). These effects did not significantly differ from the respective 28% and 53% promoted by the well known angiogenic growth factor FGF-2 (50 ng/mL). In the in vivo vasculoangiogenesis YSM assay on 2 to 4-day old embryos, GS (0.001-0.1mg/disk) and, to a lesser extent, CS (0.030-0.1mg/disk) increased the amount of vessels relative to control (P < 0.05). The effects of administration of CS and GS (0.1mg/disk) did not differ from what was observed in groups treated with 50 ng/mL FGF2. In the CAM angiogenesis assay on 6 to 8-days old embryos, again both CS and GS increased the amount of vessels relative to control, but only in concentrations as high as 2.0 mg/disk. This effect was no different from what was observed in groups treated with 50 ng/mL FGF2. The pro-angiogenic effects of CS (2 mg/disk) in embryonary angiogenesis were confirmed in the advanced angiogenesis of mice: only the group treated with CS (2 mg/implant) displayed a significant increase in the amount of blood vessels, expressed as hemoglobin content (0.52 ± 0.08g/dL), relative to control (vehicle; PBS; 0.20 ± 0.07 g/dL). This pro-angiogenic effect was no different than that of FGF2 (0.53 ± 0.1g/dL). The in vitro and in vivo results indicate the pro-angiogenic properties of CS and GS. However, CS (GAG) was the more effective compound in the tests performed. As a constituent of proteoglycans, it is suggested that CS exerts its effects by interacting with FGF and other angiogenic factors in the extracellular matrix, stabilizing the receptor, and thus positively modulating the pro-angiogenic signal in endothelial cells. While the cellular mechanisms underlying CS and GS activity demand more specific research, there is an evident potential therapeutic use for both compounds in clinical situations, such as those related to vascular discrepancy. |
| id |
URPE_cd2d22109f298878fc888d31c7ed1b1a |
|---|---|
| oai_identifier_str |
oai:tede2:tede2/4574 |
| network_acronym_str |
URPE |
| network_name_str |
Biblioteca Digital de Teses e Dissertações da UFRPE |
| repository_id_str |
|
| spelling |
NOGUEIRA, Romildo de AlbuquerqueDIAS, Paulo FernandoCATANHO, Maria Teresa Jansem de AlmeidaFERNANDES, Thiago de Salazar eLEÃO, Ana Maria dos Anjos CarneiroTENÓRIO, Bruno Mendeshttp://lattes.cnpq.br/7321834692967377BORBA, Fernanda Katharine de Souza Lins2016-06-01T16:45:23Z2012-02-29BORBA, Fernanda Katharine de Souza Lins. Estudo da atividade dos sulfatos de condroitina e glucosamina na formação de vasos sanguíneos em modelos in vitro e in vivo. 2012. 186 f. Tese (Programa de Pós-Graduação em Biociência Animal) - Universidade Federal Rural de Pernambuco, Recife.http://www.tede2.ufrpe.br:8080/tede2/handle/tede2/4574ark:/57462/0013000005d5gChondroitin Sulfate (CS) and Glucosamine Sulfate (GS) are functional constituents of vertebrate tissues. GS is an amino sugar and CS is part of the glucosaminoglycans group (GAGs). Studies have suggested CS and GS to have anti-inflammatory properties, however it has also been shown that these compounds promote scarring and proliferation of fibroblasts, which express molecules important for blood vessel growth (angiogenesis). This study was aimed at evaluating the effects of CS and GS on in vitro models regarding cell viability (cytotoxicity - MTT), proliferation (BrdU incorporation) and differentiation (tubulogenesis in Matrigel support) on human umbilical vein endothelial cells (HUVEC line). In vivo angiogenesis was also evaluated in (1) extraembryonic membranes of Gallus domesticus (number of chorioallantoic vessels - CAM assay and vitelinic YSM assay; and fractal geometry analysis); (2) and subcutaneous tissue of adult mice (Mus muscullus) by hemoglobin quantification (Spectroscopy) in Gelfoam implants. In the HUVEC assay, both CS and GS (1-3000 g/mL) displayed partial cytotoxic effect (~50% viability), but only in the highest tested concentrations (3000 and 1000 g/mL). It was observed that CS (3 g/mL), but not GS, promoted proliferation and tubulogenesis of HUVEC in 40% (P < 0.05) and 64% (P < 0.05), respectively, relative to control (RPMI-1640 medium). These effects did not significantly differ from the respective 28% and 53% promoted by the well known angiogenic growth factor FGF-2 (50 ng/mL). In the in vivo vasculoangiogenesis YSM assay on 2 to 4-day old embryos, GS (0.001-0.1mg/disk) and, to a lesser extent, CS (0.030-0.1mg/disk) increased the amount of vessels relative to control (P < 0.05). The effects of administration of CS and GS (0.1mg/disk) did not differ from what was observed in groups treated with 50 ng/mL FGF2. In the CAM angiogenesis assay on 6 to 8-days old embryos, again both CS and GS increased the amount of vessels relative to control, but only in concentrations as high as 2.0 mg/disk. This effect was no different from what was observed in groups treated with 50 ng/mL FGF2. The pro-angiogenic effects of CS (2 mg/disk) in embryonary angiogenesis were confirmed in the advanced angiogenesis of mice: only the group treated with CS (2 mg/implant) displayed a significant increase in the amount of blood vessels, expressed as hemoglobin content (0.52 ± 0.08g/dL), relative to control (vehicle; PBS; 0.20 ± 0.07 g/dL). This pro-angiogenic effect was no different than that of FGF2 (0.53 ± 0.1g/dL). The in vitro and in vivo results indicate the pro-angiogenic properties of CS and GS. However, CS (GAG) was the more effective compound in the tests performed. As a constituent of proteoglycans, it is suggested that CS exerts its effects by interacting with FGF and other angiogenic factors in the extracellular matrix, stabilizing the receptor, and thus positively modulating the pro-angiogenic signal in endothelial cells. While the cellular mechanisms underlying CS and GS activity demand more specific research, there is an evident potential therapeutic use for both compounds in clinical situations, such as those related to vascular discrepancy.Sulfato de glucosamina (SG) e Sulfato de condroitina (SC) são constituintes funcionais dos tecidos de vertebrados. O SG é um aminoaçúcar e o SC integra o grupo das glicosaminoglicanas (GAG). Estudos apontam propriedades antiinflamatórias do SC e SG, e demonstram ainda que essas substâncias promovem a cicatrização e a proliferação de fibroblastos, os quais expressam moléculas que atuam na formação de vasos sanguíneos (angiogênese). Os objetivos deste estudo foram avaliar a ação do SC e SG em modelos in vitro sobre a viabilidade (citotoxicidade pelo MTT), proliferação (incorporação por BrdU) e diferenciação (tubulogênese em suporte matrigel) na linhagem de células endoteliais de veia umbilical humana (HUVEC). Também se investigou a angiogênese in vivo: (1) em membranas anexas de embriões de Gallus domesticus (número de vasos corioalantóides - ensaio da CAM, e vitelínicos – ensaio da YSM; e análise por geometria fractal); (2) e no tecido subcutâneo de camundongos adultos por meio de quantificação da hemoglobina em implantes de Gelfoam. No ensaio com HUVEC, SC e SG (1-3000 g/mL) exerceram efeito citotóxico parcial (~50% de viabilidade), e somente nas respectivas maiores concentrações (3000 e 1000 g/mL). Verificou-se que o SC (3 g/mL), mas não o SG, estimulou a proliferação e a tubulogênese de HUVEC em 40% (p < 0,05) e em 64% (p < 0,05) respectivamente, em relação ao controle (meio RPMI-1640). Estes efeitos não diferiram estatisticamente dos 28% e 53%, respectivamente, promovidos pelo bem conhecido fator de crescimento angiogênico FGF-2 (50 ng/mL). No ensaio de vasculo-angiogênese na YSM de embriões de 2-4 dias de idade o SG (0,001-0,1mg/disco) principalmente, e o SC (0,030-0,1mg/disco) aumentaram o número de vasos em relação ao grupo controle (p < 0,05). Os efeitos da administração de SC e SG (0,1 mg/disco) não diferiram do observado no grupo tratado com 50 ng/mL de FGF-2. No ensaio de angiogênese na CAM de embriões de 6-8 dias de idade, ambos, SC e SG também elevaram o número de vasos em relação ao controle na concentração elevada de 2,0 mg/disco. Este efeito também não diferiu do observado no grupo exposto a 50 ng/mL de FGF- 2. O efeito pró-angiogênico do SC (2 mg/disco) na angiogênese embrionária foi confirmado na angiogênese avançada de camundongos adultos. Apenas o grupo que recebeu SC (2 mg/implante) mostrou um aumento significativo de vasos sanguíneos, expresso como conteúdo de hemoglobina (0,52 ± 0,08g/dL), comparado ao controle (veículo; PBS; 0,20 ± 0,07 g/dL). Este efeito pró-angiogênico não diferiu do obtido com FGF2 (0,53 ± 0.1g/dL). Os resultados in vitro e in vivo demonstram as propriedades pró-angiogênicas do SC e SG, contudo o SC (GAG) foi o mais efetivo nos ensaios. Como um constituinte de proteoglicanas, o SC sugere exercer seus efeitos pela interação com o FGF e outros fatores angiogênicos na matriz extracelular, estabilizando-os nos receptores e modulando assim, positivamente, o sinal pró-angiogênico nas células endoteliais. Embora mecanismos celulares subjacentes à atividade de SC e SG demandem mais estudos, evidencia-se um potencial papel terapêutico das duas substâncias em situações clínicas relacionadas à defasagem vascular.Submitted by (lucia.rodrigues@ufrpe.br) on 2016-06-01T16:45:23Z No. of bitstreams: 1 Fernanda Katharine de Souza Lins Borba.pdf: 4059966 bytes, checksum: cce20c494a8d5b3926e4508d0ff50750 (MD5)Made available in DSpace on 2016-06-01T16:45:23Z (GMT). No. of bitstreams: 1 Fernanda Katharine de Souza Lins Borba.pdf: 4059966 bytes, checksum: cce20c494a8d5b3926e4508d0ff50750 (MD5) Previous issue date: 2012-02-29Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPESapplication/pdfporUniversidade Federal Rural de PernambucoPrograma de Pós-Graduação em Biociência AnimalUFRPEBrasilDepartamento de Morfologia e Fisiologia AnimalSulfato de condroitinaSulfato de glucosaminaAngiogêneseVasculogêneseDimensão fractalCélulas endoteliaisVeia umbilical humanaChondroitin sulfateGlucosamine sulfateAngiogenesisVasculogenesisFractal dimensionHuman umbilical veinEndothelial cellsCIENCIAS AGRARIAS::MEDICINA VETERINARIAEstudo da atividade dos sulfatos de condroitina e glucosamina na formação de vasos sanguíneos em modelos in vitro e in vivoinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesis-1510757014399315592600600600600-89223641879873962044536702642350173193590462550136975366info:eu-repo/semantics/openAccessreponame:Biblioteca Digital de Teses e Dissertações da UFRPEinstname:Universidade Federal Rural de Pernambuco (UFRPE)instacron:UFRPELICENSElicense.txtlicense.txttext/plain; charset=utf-82089http://www.tede2.ufrpe.br:8080/tede2/bitstream/tede2/4574/1/license.txt7b5ba3d2445355f386edab96125d42b7MD51ORIGINALFernanda Katharine de Souza Lins Borba.pdfFernanda Katharine de Souza Lins Borba.pdfapplication/pdf4059966http://www.tede2.ufrpe.br:8080/tede2/bitstream/tede2/4574/2/Fernanda+Katharine+de+Souza+Lins+Borba.pdfcce20c494a8d5b3926e4508d0ff50750MD52tede2/45742024-02-23 15:41:18.672oai:tede2: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Biblioteca Digital de Teses e Dissertaçõeshttp://www.tede2.ufrpe.br:8080/tede/PUBhttp://www.tede2.ufrpe.br:8080/oai/requestbdtd@ufrpe.br ||bdtd@ufrpe.bropendoar:2024-02-23T18:41:18Biblioteca Digital de Teses e Dissertações da UFRPE - Universidade Federal Rural de Pernambuco (UFRPE)false |
| dc.title.por.fl_str_mv |
Estudo da atividade dos sulfatos de condroitina e glucosamina na formação de vasos sanguíneos em modelos in vitro e in vivo |
| title |
Estudo da atividade dos sulfatos de condroitina e glucosamina na formação de vasos sanguíneos em modelos in vitro e in vivo |
| spellingShingle |
Estudo da atividade dos sulfatos de condroitina e glucosamina na formação de vasos sanguíneos em modelos in vitro e in vivo BORBA, Fernanda Katharine de Souza Lins Sulfato de condroitina Sulfato de glucosamina Angiogênese Vasculogênese Dimensão fractal Células endoteliais Veia umbilical humana Chondroitin sulfate Glucosamine sulfate Angiogenesis Vasculogenesis Fractal dimension Human umbilical vein Endothelial cells CIENCIAS AGRARIAS::MEDICINA VETERINARIA |
| title_short |
Estudo da atividade dos sulfatos de condroitina e glucosamina na formação de vasos sanguíneos em modelos in vitro e in vivo |
| title_full |
Estudo da atividade dos sulfatos de condroitina e glucosamina na formação de vasos sanguíneos em modelos in vitro e in vivo |
| title_fullStr |
Estudo da atividade dos sulfatos de condroitina e glucosamina na formação de vasos sanguíneos em modelos in vitro e in vivo |
| title_full_unstemmed |
Estudo da atividade dos sulfatos de condroitina e glucosamina na formação de vasos sanguíneos em modelos in vitro e in vivo |
| title_sort |
Estudo da atividade dos sulfatos de condroitina e glucosamina na formação de vasos sanguíneos em modelos in vitro e in vivo |
| author |
BORBA, Fernanda Katharine de Souza Lins |
| author_facet |
BORBA, Fernanda Katharine de Souza Lins |
| author_role |
author |
| dc.contributor.advisor1.fl_str_mv |
NOGUEIRA, Romildo de Albuquerque |
| dc.contributor.advisor-co1.fl_str_mv |
DIAS, Paulo Fernando |
| dc.contributor.referee1.fl_str_mv |
CATANHO, Maria Teresa Jansem de Almeida |
| dc.contributor.referee2.fl_str_mv |
FERNANDES, Thiago de Salazar e |
| dc.contributor.referee3.fl_str_mv |
LEÃO, Ana Maria dos Anjos Carneiro |
| dc.contributor.referee4.fl_str_mv |
TENÓRIO, Bruno Mendes |
| dc.contributor.authorLattes.fl_str_mv |
http://lattes.cnpq.br/7321834692967377 |
| dc.contributor.author.fl_str_mv |
BORBA, Fernanda Katharine de Souza Lins |
| contributor_str_mv |
NOGUEIRA, Romildo de Albuquerque DIAS, Paulo Fernando CATANHO, Maria Teresa Jansem de Almeida FERNANDES, Thiago de Salazar e LEÃO, Ana Maria dos Anjos Carneiro TENÓRIO, Bruno Mendes |
| dc.subject.por.fl_str_mv |
Sulfato de condroitina Sulfato de glucosamina Angiogênese Vasculogênese Dimensão fractal Células endoteliais Veia umbilical humana |
| topic |
Sulfato de condroitina Sulfato de glucosamina Angiogênese Vasculogênese Dimensão fractal Células endoteliais Veia umbilical humana Chondroitin sulfate Glucosamine sulfate Angiogenesis Vasculogenesis Fractal dimension Human umbilical vein Endothelial cells CIENCIAS AGRARIAS::MEDICINA VETERINARIA |
| dc.subject.eng.fl_str_mv |
Chondroitin sulfate Glucosamine sulfate Angiogenesis Vasculogenesis Fractal dimension Human umbilical vein Endothelial cells |
| dc.subject.cnpq.fl_str_mv |
CIENCIAS AGRARIAS::MEDICINA VETERINARIA |
| description |
Chondroitin Sulfate (CS) and Glucosamine Sulfate (GS) are functional constituents of vertebrate tissues. GS is an amino sugar and CS is part of the glucosaminoglycans group (GAGs). Studies have suggested CS and GS to have anti-inflammatory properties, however it has also been shown that these compounds promote scarring and proliferation of fibroblasts, which express molecules important for blood vessel growth (angiogenesis). This study was aimed at evaluating the effects of CS and GS on in vitro models regarding cell viability (cytotoxicity - MTT), proliferation (BrdU incorporation) and differentiation (tubulogenesis in Matrigel support) on human umbilical vein endothelial cells (HUVEC line). In vivo angiogenesis was also evaluated in (1) extraembryonic membranes of Gallus domesticus (number of chorioallantoic vessels - CAM assay and vitelinic YSM assay; and fractal geometry analysis); (2) and subcutaneous tissue of adult mice (Mus muscullus) by hemoglobin quantification (Spectroscopy) in Gelfoam implants. In the HUVEC assay, both CS and GS (1-3000 g/mL) displayed partial cytotoxic effect (~50% viability), but only in the highest tested concentrations (3000 and 1000 g/mL). It was observed that CS (3 g/mL), but not GS, promoted proliferation and tubulogenesis of HUVEC in 40% (P < 0.05) and 64% (P < 0.05), respectively, relative to control (RPMI-1640 medium). These effects did not significantly differ from the respective 28% and 53% promoted by the well known angiogenic growth factor FGF-2 (50 ng/mL). In the in vivo vasculoangiogenesis YSM assay on 2 to 4-day old embryos, GS (0.001-0.1mg/disk) and, to a lesser extent, CS (0.030-0.1mg/disk) increased the amount of vessels relative to control (P < 0.05). The effects of administration of CS and GS (0.1mg/disk) did not differ from what was observed in groups treated with 50 ng/mL FGF2. In the CAM angiogenesis assay on 6 to 8-days old embryos, again both CS and GS increased the amount of vessels relative to control, but only in concentrations as high as 2.0 mg/disk. This effect was no different from what was observed in groups treated with 50 ng/mL FGF2. The pro-angiogenic effects of CS (2 mg/disk) in embryonary angiogenesis were confirmed in the advanced angiogenesis of mice: only the group treated with CS (2 mg/implant) displayed a significant increase in the amount of blood vessels, expressed as hemoglobin content (0.52 ± 0.08g/dL), relative to control (vehicle; PBS; 0.20 ± 0.07 g/dL). This pro-angiogenic effect was no different than that of FGF2 (0.53 ± 0.1g/dL). The in vitro and in vivo results indicate the pro-angiogenic properties of CS and GS. However, CS (GAG) was the more effective compound in the tests performed. As a constituent of proteoglycans, it is suggested that CS exerts its effects by interacting with FGF and other angiogenic factors in the extracellular matrix, stabilizing the receptor, and thus positively modulating the pro-angiogenic signal in endothelial cells. While the cellular mechanisms underlying CS and GS activity demand more specific research, there is an evident potential therapeutic use for both compounds in clinical situations, such as those related to vascular discrepancy. |
| publishDate |
2012 |
| dc.date.issued.fl_str_mv |
2012-02-29 |
| dc.date.accessioned.fl_str_mv |
2016-06-01T16:45:23Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/doctoralThesis |
| format |
doctoralThesis |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
BORBA, Fernanda Katharine de Souza Lins. Estudo da atividade dos sulfatos de condroitina e glucosamina na formação de vasos sanguíneos em modelos in vitro e in vivo. 2012. 186 f. Tese (Programa de Pós-Graduação em Biociência Animal) - Universidade Federal Rural de Pernambuco, Recife. |
| dc.identifier.uri.fl_str_mv |
http://www.tede2.ufrpe.br:8080/tede2/handle/tede2/4574 |
| dc.identifier.dark.fl_str_mv |
ark:/57462/0013000005d5g |
| identifier_str_mv |
BORBA, Fernanda Katharine de Souza Lins. Estudo da atividade dos sulfatos de condroitina e glucosamina na formação de vasos sanguíneos em modelos in vitro e in vivo. 2012. 186 f. Tese (Programa de Pós-Graduação em Biociência Animal) - Universidade Federal Rural de Pernambuco, Recife. ark:/57462/0013000005d5g |
| url |
http://www.tede2.ufrpe.br:8080/tede2/handle/tede2/4574 |
| dc.language.iso.fl_str_mv |
por |
| language |
por |
| dc.relation.program.fl_str_mv |
-1510757014399315592 |
| dc.relation.confidence.fl_str_mv |
600 600 600 600 |
| dc.relation.department.fl_str_mv |
-8922364187987396204 |
| dc.relation.cnpq.fl_str_mv |
453670264235017319 |
| dc.relation.sponsorship.fl_str_mv |
3590462550136975366 |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Universidade Federal Rural de Pernambuco |
| dc.publisher.program.fl_str_mv |
Programa de Pós-Graduação em Biociência Animal |
| dc.publisher.initials.fl_str_mv |
UFRPE |
| dc.publisher.country.fl_str_mv |
Brasil |
| dc.publisher.department.fl_str_mv |
Departamento de Morfologia e Fisiologia Animal |
| publisher.none.fl_str_mv |
Universidade Federal Rural de Pernambuco |
| dc.source.none.fl_str_mv |
reponame:Biblioteca Digital de Teses e Dissertações da UFRPE instname:Universidade Federal Rural de Pernambuco (UFRPE) instacron:UFRPE |
| instname_str |
Universidade Federal Rural de Pernambuco (UFRPE) |
| instacron_str |
UFRPE |
| institution |
UFRPE |
| reponame_str |
Biblioteca Digital de Teses e Dissertações da UFRPE |
| collection |
Biblioteca Digital de Teses e Dissertações da UFRPE |
| bitstream.url.fl_str_mv |
http://www.tede2.ufrpe.br:8080/tede2/bitstream/tede2/4574/1/license.txt http://www.tede2.ufrpe.br:8080/tede2/bitstream/tede2/4574/2/Fernanda+Katharine+de+Souza+Lins+Borba.pdf |
| bitstream.checksum.fl_str_mv |
7b5ba3d2445355f386edab96125d42b7 cce20c494a8d5b3926e4508d0ff50750 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
| repository.name.fl_str_mv |
Biblioteca Digital de Teses e Dissertações da UFRPE - Universidade Federal Rural de Pernambuco (UFRPE) |
| repository.mail.fl_str_mv |
bdtd@ufrpe.br ||bdtd@ufrpe.br |
| _version_ |
1867617992933638144 |